Dyne Therapeutics
197 hedge funds and large institutions have $1.23B invested in Dyne Therapeutics in 2025 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 95 increasing their positions, 53 reducing their positions, and 30 closing their positions.
79% more repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 53
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
5.29% more ownership
Funds ownership: 107.86% → 113.15% (+5.3%)
5% less capital invested
Capital invested by funds: $1.29B → $1.23B (-$62.7M)
4% less funds holding
Funds holding: 205 → 197 (-8)
23% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 30
53% less call options, than puts
Call options by funds: $390K | Put options by funds: $823K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$35.1M |
| 2 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$23.3M |
| 3 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$16M |
| 4 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$15.9M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
+$15.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$22.7M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$20.9M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$15.5M |
| 4 |
VPC
Vestal Point Capital
New York
|
-$11.8M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$10.1M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SC
226
Stephens Consulting
Flint,
Michigan
| – | -$367 | -35 | Closed |
|
227
Amundi
Paris,
France
| – | -$198 | -21 | Closed |
|
|
WCM
228
WealthTrak Capital Management
Virginia Beach,
Virginia
| – | -$210 | -20 | Closed |
|
DYN Hedge Fund Activity: Q2 2025 in Review
197 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q2 2025, worth a combined $1.23B — down 4.9% from $1.29B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of DYN and 23 opened new positions — a net loss of 7 holders — while 53 trimmed existing stakes and 95 added.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $35.1M. The largest seller was Citadel Advisors, cutting an estimated $22.7M.
- 197 institutional investors held Dyne Therapeutics (DYN) as of Q2 2025, down from 205 in Q1 2025.
- Funds reported $1.23B of Dyne Therapeutics stock for Q2 2025, down 4.9% quarter-over-quarter.
- 23 funds opened new Dyne Therapeutics positions in Q2 2025 and 30 closed out, a net change of -7 holders.
- The largest Dyne Therapeutics buyer in Q2 2025 was Adage Capital Partners, an estimated $35.1M added.
- The largest Dyne Therapeutics seller in Q2 2025 was Citadel Advisors, an estimated $22.7M sold.
Based on aggregated 13F filings for Q2 2025.